3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
venetoclax
108
Azacitidine
92
Cytarabine
77
Specimen Handling
52
fludarabine
47
Biopsy
38
Daunorubicin
31
Cyclophosphamide
31
Injections
29
Decitabine
29
Idarubicin
27
fludarabine phosphate
25
Granulocyte Colony-Stimulating Factor
22
Busulfan
22
Whole-Body Irradiation
20
Mycophenolic Acid
20
Tacrolimus
18
decitabine and cedazuridine drug combination
17
Melphalan
17
CPX-351
17
Stem Cell Transplantation
16
gilteritinib
14
Mitoxantrone
14
ivosidenib
13
Filgrastim
13
Peripheral Blood Stem Cell Transplantation
12
Cladribine
12
Magnetic Resonance Spectroscopy
11
Etoposide
11
Cyclosporine
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA